We appreciate the commentary by Prof. Horsburgh on our article, particularly as it stimulates further discussion on where the true annual risk of infection (ARI) of Mycobacterium tuberculosis lies. Even though the phenomenon of immunoreactivity reversion is neither new nor rare, its implications for the estimation of the ARI have been largely dismissed. Given how the ARI is calculated, the observed changes in immunoreactivity lead to concrete discrepancies in the metric when accounting for reversion. Our work explored how ARI estimation is affected when accounting for varying reversion probabilities ranging from 0% per year to 50% per year, covering a wide range of scenarios. Note that in our paper and this response, we consider reversion the observed process of waning immunoreactivity, rather than an underlying mechanism such as self-cure...